BiOptix Diagnostics

About BiOptix Diagnostics

Founded in 2003 by Oyvind Nilsen and Slava Petropavlovskikh, BiOptix Diagnostics is a company that has developed a new class of analytical biosensor instrumentation. The company's proprietary Enhanced Surface Plasmon Resonance (ESPR) technology, developed in collaboration with 2005 Nobel Prize laureate in physics John Hall, is used for the detection of molecular interactions.

BiOptix's main product, the 404pi, is a label-free, real-time kinetic analysis instrument that provides scientists with the ability to study protein-protein and protein-small molecule interactions. This technology has broad applications in drug discovery, vaccine development, cancer diagnostics, allergy testing, immunology, and infectious disease research.

The company's business model is focused on providing these advanced analytical instruments to researchers in the biotechnology and pharmaceutical industries. By offering high-throughput, label-free technology, BiOptix aims to accelerate the pace of scientific discovery and drug development.